About our DMPK Webinar on Drug Transporters

Drug transporters are the unsung heroes of pharmacokinetics. They shape absorption, distribution, and excretion across key organs and tissues like the intestine, liver, kidney, and brain. If you’re involved in drug discovery or development, understanding transporters isn’t just optional, it’s necessary!

If you want to design smarter drugs, boost bioavailability and avoid costly failures, join us for this exclusive webinar. World-leading expert Professor Sugiyama and Pharmaron specialist Chunyan Han will explore how transporter studies can transform drug discovery and development strategies and help you understand why their function is critical for optimizing drug delivery, improving bioavailability, and reducing off-target toxicity.

Register to watch our webinar on-demand

You can ask your own questions of our experts.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State

Email(Required)

Thank you for registering to watch our on-demand webinar. By submitting this form, you consent to the collection and processing of your personal data by Pharmaron in accordance with our Privacy Policy. You may be contacted by email following your webinar viewing regarding any questions you may have, as well as relevant services and updates. You can unsubscribe or withdraw your consent at any time.

What You’ll Learn

By attending this webinar, you will learn:

How transporter expression systems enable screening of compound–transporter interactions to guide lead compound selection
The impact of genetic polymorphisms and transporter-mediated drug–drug interactions on pharmacokinetics and patient safety
Strategies to leverage transporter insights for optimizing compound selection and real-world clinical performance

Meet our Speakers

Moderated by:

Barry Jones, Ph.D. – Chief Scientist, Global DMPK at Pharmaron

Dr. Barry Jones is the chief scientist for Pharmaron Global DMPK based at Hoddesdon and Rushden in the UK. Prior to this, Barry worked in the pharmaceutical industry firstly at Pfizer Global Research & Development in Sandwich from 1990 to 2011 before joining Astrazeneca in 2011 until 2019. Throughout his industrial career he has focused on setting strategic direction, identifying new opportunities for research/development programs and adding significant insight/expertise and value to drug discovery and development projects with a focus in the area of in vitro DMPK science and drug-drug interactions. Barry gained his Ph. D. from the University of Surrey following research into cytochrome P450-mediated N-dealkylation 1990. He is a long-standing member of the Xenobiotica editorial board and has authored or co-authored more than 80 publications.

Speakers:

Yuichi Sugiyama, Ph.D. – Distinguished Adjunct Professor at ShanghaiTech University

Yuichi Sugiyama has served as Special Professor Emeritus at Josai International University since April 1, 2021. He earned his Ph.D. in Pharmacy from the University of Tokyo in 1978. After retiring from the university in 2012, he continued research at the RIKEN Innovation Center as head of the Sugiyama Laboratory. Dr. Sugiyama’s groundbreaking work in physiologically based pharmacokinetics has greatly advanced in vitro–in vivo extrapolation, especially in predicting drug clearance and drug-drug interactions in humans. His studies on membrane transporters—focusing on function, kinetics, and genetic variation—have been pivotal in understanding drug disposition. He has also led major organizations, serving as President of both the International and Japanese Societies for the Study of Xenobiotics (2006–2007), promoting global research in drug metabolism and transport.

Chunyan Han – Executive Director ADME at Pharmaron

Dr. Chunyan Han serves as Executive Director of the ADME Department at Pharmaron and is a member of the company’s Global DMPK Leadership Team. She oversees the new modality, innovation, omics, PBPK, and MPS teams. Dr. Han earned her Ph.D. in Medicinal Chemistry from Peking Union Medical College and an M.Sc. in PBPK Modeling from the University of Manchester. With more than 16 years of hands-on experience in ADME sciences and translational modeling, Dr. Han has contributed to numerous integrated drug discovery programs from lead identification through IND submission. She has deep expertise in transporter-related absorption and disposition, having established IVIVE strategies that integrate both metabolic enzyme activity and key transporter mechanisms. Her team’s PBPK modeling has contributed to human dose prediction, formulation optimization, and early evaluation of drug-drug interaction risk, including interactions mediated by transporters, for a broad range of partners.